Skip to main content

Table 1 Characters of included 32 papers about the prognostic value of miR-221 in human carcinomas

From: Prognostic value of miR-221 in human malignancy: evidence from 3041 subjects

Study

Nation

Patients

cancer

Survival

HR(95% CI)

P value

Origins

Measure

Cutoff

Analysis

Wu Q (2017)

China

74

Ovarian cancer

OS

0.395 (0.196–0.796)

0.009

Tumor

qRT-PCR

Median

Univariate

Tsikrika (2017)

Greece

159

Bladder cancer

DFS

PFS

0.712(0.380–1.335)

1.396(0.539–3.620)

0.290

0.492

Tumor

qRT-PCR

ROC

Univariate

Deng (2017)

China

125

Breast cancer

DFS

0.480 (0.263–0.879)

0.017

Tumor

qRT-PCR

Median

Multivariate

Nakka (2017)

USA

32

Osteosarcoma

OS

0.733(0.486–1.1055)

0.139

Tumor

qRT-PCR/ISH

Quartation

Multivariate

Xie D (2017)

China

70

Live cancer

OS

1.743 (1.004–3.772)

0.012

Tumor

qRT-PCR

Median

Multivariate

Hussein (2017)

Egypt

50

Laryngeal cancer

OS

6.5 (1.8–22.5)

0.003

Tumor

qRT-PCR

ROC

Univariate

Dai L (2017)

China

78

Thyroid cancer

RFS

1.41(1.14–1.95)

0.007

Tumor

qRT-PCR

Median

Multivariate

Chen F (2017)

China

135

HCC

DFS

OS

2.846 (1.564–5.181)

2.969 (1.629–5.408)

0.001

< 0.001

Tumor

qRT-PCR

Median

Multivariate

Zhang Y (2016)

China

104

Lung cancer

OS

1.873(1.267–2.768)

0.002

Tumor

qRT-PCR

Median

Multivariate

Yang Z (2015)

China

108

Osteosarcoma

OS

RFS

7.66(1.83–15.92)

6.82(1.33–13.69)

0.01

0.01

Serum

qRT-PCR

Median

Multivariate

Cai K (2015)

China

182

Colon cancer

OS

2.394 (1.210–4.910)

0.006

Tumor

qRT-PCR

Median

Multivariate

Tao K (2014)

China

90

Colon cancer

OS

2.043 (1.095–3.812)

0.025

Tumor

qRT-PCR

Median

Multivariate

Vergho (2014)

Germany

74

Renal cancer

CSS

0.47 (0.22–1.00)

0.0527

Tumor

qRT-PCR

ROC

Multivariate

Lv J (2014)

China

117

Lung cancer

OS

2.425 (1.314–4.475)

0.005

Tumor

qRT-PCR

Median

Multivariate

Li P (2014)

China

72

CMM

OS

DFS

3.189(1.782–6.777)

2.119(1.962–8.552)

0.007

0.01

Serum

qRT-PCR

Median

Multivariate

Gyongyosi B (2014)

Italy

20

HCC

OS

PFS

1.92(0.61–6.10)

1.32(0.47–3.66)

0.29

0.58

Tumor

qRT-PCR

Median

Univariate

Falkenberg (2013)

Germany

86

Breast cancer

MFS

2.57(1.1073–5.9647)

0.028

Tumor

qRT-PCR

ROC

Multivariate

Hong (2013)

China

96

Ovarian cancer

OS

2.243(1.1357–4.4300)

0.020

Serum

qRT-PCR

Mean

Multivariate

Gimenes (2013)

Brazil

48

ALL

OS

DFS

2.31(0.92–5.81)

1.54 (0.57–4.17)

0.074

0.391

Marrow

qRT-PCR

Median

Multivariate

Karakatsanis (2013)

Greece

60

HCC

OS

1.72 (1.32–2.50)

0.002

Tumor

qRT-PCR

Mean

Multivariate

Amankwah (2013)

USA

65

Prostate cancer

RFS

1.79 (0.67–4.76)

0.25

Tumor

qRT-PCR

Median

Multivariate

Liu K (2012)

China

92

Gastric cancer

OS

2.322 (1.1116–4.8505)

0.025

Tumor

qRT-PCR

Mean

Multivariate

Hanna (2012)

USA

377

Breast cancer

OS

0.70 (0.51–0.97)

0.0312

Tumor

ISH

Quartation

Multivariate

Kang (2012)

Korea

92

Prostate cancer

RFS

0.360 (0.171–1.896)

0.570

Tumor

qRT-PCR

Median

Univariate

Li J (2011)

China

46

HCC

OS

1.903(1.235–2.981)

0.018

Serum

qRT-PCR

Mean

Multivariate

Yoon (2011)

Korea

115

HCC

RFS

3.07 (1.56–6.07)

0.001

Tumor

qRT-PCR

Mean

Multivariate

Zhao R (2011)

China

93

Breast cancer

OS

6.871 (1.967–23.997)

0.003

plasma

qRT-PCR

Median

Multivariate

Schaefer (2010)

Germany

75

Prostate cancer

RFS

0.93 (0.3–2.89)

0.902

Tumor

qRT-PCR

Median

Univariate

Wang (2010)

China

32

ALL

OS

0.538(0.30–0.9648)

0.038

Marrow

qRT-PCR

Median

Multivariate

Spahn (2010)

Germany

92

Prostate cancer

RFS

0.525(0.29–0.95)

0.032

Tumor

qRT-PCR

ROC

Multivariate

Pu (2010)

China

103

Colon cancer

OS

3.478(1.038–11.654)

0.043

Plasma

qRT-PCR

Youden

Multivariate

Guo (2010)

China

79

Lymphoma

OS

5.714(1.782–18.18)

0.003

Plasma

qRT-PCR

Youden

Multivariate

  1. Note: HCC Hepatocellular carcinoma; ALL Acute lymphoid leukemia; CMM Cutaneous malignant melanoma; ROC Receiver operating characteristic curve; Youden, Youden index; OS Overall survival; RFS Relapse-free survival; DFS Disease-free survival; PFS Progression-free survival; CSS Cancer-special survival; MFS Metastasis-free survival; qRT-PCR Quantitative Real Time PCR; ISH In-situ hybridization